Program
pralatrexate
Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aurobindo Pharma | 122 open or running | phase 3since Sep 19, 2023 | Aug 14, 2006 | Feb 2027phase 1 · NCT07036133 |
| Zydus Lifesciences | 40 open or running | phase 3since Aug 18, 2011 | Jan 24, 2003 | none ahead |
| Mundipharma | 30 open or running | phase 4since May 5, 2017 | Dec 4, 2013 | none ahead |
Also a collaborator on its studies: axis-clinicals-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jan 24, 2003.
- Jul 23, 2008Phase 2 study in Carcinoma, Transitional CellAurobindo Pharma · NCT00722553 · 30 enrolled · United States, Argentina, Belgium and more
- Oct 19, 2009Phase 2 study in Lymphoma, B-CellZydus Lifesciences · NCT00998946 · 29 enrolled · United States
- May 5, 2010Phase 2 study in Breast NeoplasmsAurobindo Pharma · NCT01118624 · 22 enrolled · United States, Czechia, France and more
- May 28, 2010Phase 1 study in Lymphoma, T-Cell, CutaneousAurobindo Pharma · NCT01134341 · 34 enrolled · United States, Italy
- Aug 18, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralZydus Lifesciences · NCT01420679 · 21 enrolled · United States, Australia, Belgium and more
- Feb 7, 2013Phase 1 study in Lymphoma, Non-HodgkinAurobindo Pharma · NCT01789723
- Mar 21, 2013Phase 1 study in Carcinoma, Non-Small-Cell LungAurobindo Pharma · NCT01820091
- Dec 4, 2013Mundipharma's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to MundipharmaMundipharma · NCT02013362 · 25 enrolled · Japan
- Mar 28, 2014Phase 2 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT02106650 · 36 enrolled · United States
- Sep 25, 2015Phase 1 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT02594267 · 48 enrolled · United States
- Jul 26, 2016Phase 3 study in Lymphoma, T-Cell, PeripheralMundipharma · NCT03349333 · 85 enrolled · China
- May 5, 2017Phase 4 study in Lymphoma, T-Cell, PeripheralMundipharma · NCT03150602 · 22 enrolled · Taiwan
- Sep 19, 2023Phase 3 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT06072131 · 504 enrolled · United States, Canada, Germany and more
- Mar 18, 2025Phase 1 study in Hematologic NeoplasmsAurobindo Pharma · NCT07036133 · 24 planned · United States
Ahead
- Feb 2027Primary completion: phase 1 study in Hematologic NeoplasmsAurobindo Pharma · NCT07036133
- Jul 2030Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT06072131
TargetBeta
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07036133Hematologic Neoplasms · United States | 1 | Recruiting | Aurobindo Pharma | Feb 2027 | 24 |
| NCT06072131Lymphoma, T-Cell, Peripheral · United States, Canada, Germany and more | 3 | Active, not recruiting | Aurobindo Pharma | Jul 2030 | 504 |
| NCT03150602Lymphoma, T-Cell, Peripheral · Taiwan | 4 | UNKNOWN | Mundipharma | Dec 31, 2020 | 22 |
| NCT03349333Lymphoma, T-Cell, Peripheral · China | 3 | Completed | Mundipharma | Jul 21, 2017 | 85 |
| NCT02594267Lymphoma, T-Cell, Peripheral · United States | 1 | Completed | Aurobindo Pharma | Apr 7, 2017 | 48 |
| NCT02106650Lymphoma, T-Cell, Peripheral · United States | 2 | Completed | Aurobindo Pharma | Oct 2018 | 36 |
| NCT02013362Lymphoma, T-Cell, Peripheral · Japan | 2 | Completed | Mundipharma | Dec 2015 | 25 |
| NCT01820091Carcinoma, Non-Small-Cell Lung | 1 | Withdrawn | Aurobindo Pharma | Apr 2015 | 0 |
| NCT01789723Lymphoma, Non-Hodgkin | 1 | Withdrawn | Aurobindo Pharma | Mar 2015 | 0 |
| NCT01420679Lymphoma, T-Cell, Peripheral · United States, Australia, Belgium and more | 3 | Terminated | Zydus Lifesciences | Dec 2017 | 21 |
| NCT01134341Lymphoma, T-Cell, Cutaneous · United States, Italy | 1 | Completed | Aurobindo Pharma | Aug 2015 | 34 |
| NCT01118624Breast Neoplasms · United States, Czechia, France and more | 2 | Completed | Aurobindo Pharma | Apr 2012 | 22 |
| NCT00998946Lymphoma, B-Cell · United States | 2 | Completed | Zydus Lifesciences | Aug 2012 | 29 |
| NCT00722553Carcinoma, Transitional Cell · United States, Argentina, Belgium and more | 2 | Completed | Aurobindo Pharma | Apr 2011 | 30 |
| NCT00606502Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Completed | Zydus Lifesciences | Jun 24, 2010 | 201 |
| NCT00554827Lymphoma, T-Cell, Cutaneous · United States | 1 | Completed | Aurobindo Pharma | Jan 2012 | 55 |
| NCT00481871Recurrence · United States | 2 | Completed | Aurobindo Pharma | May 2011 | 119 |
| NCT00364923Lymphoma, T-Cell, Peripheral · United States, Belgium, Canada and more | 2 | Completed | Aurobindo Pharma | Jan 2009 | 115 |
| NCT00052442Lymphoma · United States | 2 | Completed | Zydus Lifesciences | Mar 2009 | 72 |
How it is read
Names in the registry
- “Pralatrexate Injection”, 9 entries
- “Pralatrexate”, 4 entries
- “pralatrexate”, 2 entries
- “Folotyn”, 2 entries
- “Folotyn and Leucovorin”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 8 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lymphoma, T-Cell, Cutaneous, 2 studies
- Hematologic Neoplasms, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.